Keenova Therapeutics Plc's ROA from the first quarter of 2026 to the first quarter of 2024 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Keenova Therapeutics Plc's ROA in the first quarter of 2026?
Keenova Therapeutics Plc recorded a cumulative net loss of $-573 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -10.05%.

However, within the Healthcare sector 292 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 3191, from total ROA ranking in the fourth quarter of 2025 at 3712.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 26 2025) III. Quarter	(Mar 28 2025) I. Quarter	(Sep 27 2024) III. Quarter
Y / Y Total Assets Change	50.5 %	57.49 %	133.3 %	-4.44 %	-24.13 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-573	-486	-388	-163	1,870
Return On Assets (TTM)	-10.05 %	-9.27 %	-8.21 %	-4.62 %	52.56 %
MNK's Total Ranking	# 3191	# 3712	# 3212	#	# 3036
Total Assets (TTM) in million	5,475	5,629	8,468	3,236	3,638
Seq. Total Assets Change	-2.73 %	-33.53 %	161.71 %	-11.06 %	1.78 %
Seq. Net Income Change	-	-	-	-	-

MNK's 5 Years Annual ROA >> Back to MNK Management Effectiveness >> Compare MNK ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 100
Sector	# 293
Overall	# 3166

Return On Assets Statistics
High	Average	Low
51.31 %	-8.7 %	-52.41 %
(Sep 27 2024)		(Sep 29 2023)

Financial Statements
Keenova Therapeutics Plc's Assets	$ 5,475 million	MNK's Balance sheet
Keenova Therapeutics Plc's Income	$ -114 million	Quarterly MNK's Income Statement
MNK's Income by Division		See MNK's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 29 2023) FY 2023	(Dec 30 2022) FY 2022	FY	FY
Y / Y Total Assets Change	50.76 %	-37.92 %	-	-	-
Total Assets in million	5,629	3,734	6,014	0	0
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-490	-717	-717	0	0
Annual Return On Assets	-8.7 %	-19.21 %	-11.93 %	-	-

MNK's 5 Years Annual ROA >> Back to MNK Management Effectiveness >> Compare MNK ROA to its Competitors

More Return On Assets Ratios
MNK's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
MNK's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for MNK's Competitors
Subscribers only: Roa for Keenova Therapeutics Plc's Suppliers
Subscribers only: Return On Assets for MNK's Customers

You may also want to know
MNK's Roi	MNK's Inventory Turnover Ratio	MNK's Growth Rates	MNK's Dividend Comparisons
	MNK's Profitability Ratios	MNK's Asset Turnover Ratio	MNK's Dividend Growth
MNK's Roe	MNK's Valuation Ratios	MNK's Financial Strength Ratios	MNK's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T15:22:17+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.